[1] Barrows BR and Parks EJ. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 2006; 91: 1446-1452.
[2] Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H and Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 2011; 121: 2102-2110.
[3] Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725.e716.
[4] Chen G and Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-1635.
[5] Hotamisligil GS and Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
[6] Wang F, Yang X, Lu Y, Li Z, Xu Y, Hu J, Liu J and Xiong W. The natural product antroalbol H promotes phosphorylation of liver kinase B1 (LKB1) at threonine 189 and thereby enhances cellular glucose uptake. J Biol Chem 2019; 294: 10415-10427.
[7] Zhang BB, Zhou G and Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9: 407-416.
[8] Jaeschke A, Czech MP and Davis RJ. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev 2004; 18: 1976-1980.
[9] Weibo WEN, Mengxue JIN, Fang FANG. Clinical research of Jiangan Xiaozhi Granule in treating nonalcoholic fatty liver disease of type of qi stagnancy and blood stasis. China medicine herald, 2014,11(27):78-82..
[10] Meng Xue Jin, Weibo Wen. The clinical research about the treatment of nonalcoholic fatty liver. M.
disease with the particles for Jianganxiaozhi
[11] Xue-Hua Xie J-BL, Fang Fang, Jie Zhao, Yong-Jun Cao, Huan-Tian Cui, Hong-Wu Wang, Zhai-Yi Zhang, Zhao-Hui Sun, Yuan Yin, Wei-Bo Wen. <span>Jian-Gan-Xiao-Zhi decoction ameliorates high-fat high-carbohydrate diet-induced non-alcoholic fatty liver disease and insulin resistance by regulating the AMPK/JNK pathway</span>. <span style='display:none'>1</span>Traditional Medicine Research 1-12.
[12] Su T, Cheng BC, Fu XQ, Li T, Guo H, Cao HH, Kwan HY, Tse AK, Yu H, Cao H and Yu ZL. Comparison of the toxicities, activities and chemical profiles of raw and processed Xanthii Fructus. BMC Complement Altern Med 2016; 16: 24.
[13] Liang C, Yin J, Ma Y, Zhang X and Zhang L. Quantitative determination of characteristic components from compound of Lysionotus pauciflorus Maxim. by LC-MS/MS and its application to a pharmacokinetic study. J Pharm Biomed Anal 2020; 177: 112835.
[14] Jie Y, Mei-Zhen S, Jing W, Yun-Fei L, Pei L, Lin Q and Zhaorigetu B. In vitro cytotoxicity and in vivo acute and chronic toxicity of Xanthii Fructus and its processed product. BioMed research international 2013; 2013:
[15] Reagan-Shaw S, Nihal M and Ahmad N. Dose translation from animal to human studies revisited. Faseb j 2008; 22: 659-661.
[16] Martin SD, Morrison S, Konstantopoulos N and McGee SL. Mitochondrial dysfunction has divergent, cell type-dependent effects on insulin action. Mol Metab 2014; 3: 408-418.
[17] Ge X, Yu Q, Qi W, Shi X and Zhai Q. Chronic insulin treatment causes insulin resistance in 3T3-L1 adipocytes through oxidative stress. Free Radic Res 2008; 42: 582-591.
[18] Jin Y, Tan Y, Chen L, Liu Y and Ren Z. Reactive Oxygen Species Induces Lipid Droplet Accumulation in HepG2 Cells by Increasing Perilipin 2 Expression. Int J Mol Sci 2018; 19:
[19] Liu M, Zheng M, Cai D, Xie J, Jin Z, Liu H and Liu J. Zeaxanthin promotes mitochondrial biogenesis and adipocyte browning via AMPKalpha1 activation. Food Funct 2019; 10: 2221-2233.
[20] Li G, Luan G, He Y, Tie F, Wang Z, Suo Y, Ma C and Wang H. Polyphenol Stilbenes from Fenugreek (Trigonella foenum-graecum L.) Seeds Improve Insulin Sensitivity and Mitochondrial Function in 3T3-L1 Adipocytes. Oxid Med Cell Longev 2018; 2018: 7634362.
[21] Liu GS, Chan EC, Higuchi M, Dusting GJ and Jiang F. Redox mechanisms in regulation of adipocyte differentiation: beyond a general stress response. Cells 2012; 1: 976-993.
[22] Tian ZH, Weng JT, Shih LJ, Siao AC, Chan TY, Tsuei YW, Kuo YC, Wang TS and Kao YH. Arecoline inhibits the growth of 3T3-L1 preadipocytes via AMP-activated protein kinase and reactive oxygen species pathways. PLoS One 2018; 13: e0200508.
[23] Hwang JT, Kim SH, Lee MS, Kim SH, Yang HJ, Kim MJ, Kim HS, Ha J, Kim MS and Kwon DY. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 2007; 364: 1002-1008.
[24] Jager S, Handschin C, St-Pierre J and Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 2007; 104: 12017-12022.
[25] Herranz-Lopez M, Barrajon-Catalan E, Segura-Carretero A, Menendez JA, Joven J and Micol V. Lemon verbena (Lippia citriodora) polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms. Phytomedicine 2015; 22: 605-614.
[26] Peng IC, Chen Z, Sun W, Li YS, Marin TL, Hsu PH, Su MI, Cui X, Pan S, Lytle CY, Johnson DA, Blaeser F, Chatila T and Shyy JY. Glucagon regulates ACC activity in adipocytes through the CAMKKbeta/AMPK pathway. Am J Physiol Endocrinol Metab 2012; 302: E1560-1568.
[27] Qin Y, Yang RY, Chen MG, Shen XL and Ying-Jie HU. Inhibitory effect of cajanonic acid A on lipogenesis and lipolysis in 3T3-L1 adipocytes. Chinese Pharmacological Bulletin 2016;
[28] Kim JC, Jeon JY, Yang WS, Kim CH and Eom DW. Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease. Curr Pharm Biotechnol 2019; 20: 222-231.
[29] Ma Z, Chu L, Liu H, Wang W, Li J, Yao W, Yi J and Gao Y. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Sci Rep 2017; 7: 44819.
[30] Zhang L, Yang B and Yu B. Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice. Biol Pharm Bull 2015; 38: 1005-1011.
[31] Wang C, Li Y, Hao M and Li W. Astragaloside IV Inhibits Triglyceride Accumulation in Insulin-Resistant HepG2 Cells via AMPK-Induced SREBP-1c Phosphorylation. Front Pharmacol 2018; 9: 345.
[32] Zhou B, Zhou DL, Wei XH, Zhong RY, Xu J and Sun L. Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation. Acta Pharmacol Sin 2017; 38: 998-1008.